常山藥業(300255.SZ):CSCJC3456片Ⅰ期臨牀試驗首例受試者入組
格隆匯2月13日丨常山藥業(300255.SZ)公佈,公司與控股子公司常山凱捷健生物藥物研發(河北)有限公司(簡稱“常山凱捷健”)開展的創新藥CSCJC3456片Ⅰ期臨牀試驗,於近日完成首例受試者入組。
CSCJC3456片是由公司及常山凱捷健研發的靶向抗腫瘤藥物。CSCJC3456是一種小分子多靶點酪氨酸激酶抑制劑,通過選擇性抑制FGFR/KIT/RET/TRK等靶點而發揮抑制腫瘤細胞增殖、抑制新生血管生成、促進腫瘤凋亡的作用。臨牀前研究結果顯示,CSCJC3456對多種癌症均顯示良好的抗腫瘤作用,具有潛力在後續臨牀試驗中展現出良好的治療效果。
公司及常山凱捷健於近期完成了CSCJC3456片Ⅰ期臨牀試驗準備工作,並已於近日完成首例受試者入組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.